InvestorsHub Logo
Followers 7
Posts 1521
Boards Moderated 0
Alias Born 09/10/2015

Re: None

Friday, 02/10/2017 12:24:02 PM

Friday, February 10, 2017 12:24:02 PM

Post# of 54031
Some Facts About Potential TAUG Shareholder Value

Peak PPS of about $1.10 on 2009-06-28
Two year prior peak PPS of $0.01
1 year prior average PPS of $0.006
Current price under $0.0045
120 day moving average trend: Down

To me, there is an obvious, and persistent, pattern here.

The puffy lip balm has already been on the market for over a year and hasn't sold. What would TAUG's involvement do, to turn that around? TAUG has no money to invest in marketing relaunches and neither do the two young entrepreneurs.

TAUG's unproven marketing contacts are beginning to wear thin. Is Pfizer going to sell a re-branded puffy lip balm and source the product indirectly through TAUG? Not a chance. Neither Frank or Lynne Cesario has the clout, within Pfizer, to pull that off. And as for the reefer-oil, roll-on, muscle relaxant - it has even less of a chance. Pfizer has a solid reputation that it has earned over many years. TAUG's new snake oil roll-on product would be controversial because of fluid drug regulations and and a shady image for CBD oil products. It wouldn't make it through the first level screening.

But Pfizer isn't the only route to market for TAUG. TAUG has world-class, and indeed, world-wide, merchandising contacts. Many of them are eager to sell TAUG's new unannounced products. Does that story really sound credible to anyone?

TAUG's only hope, since it has no cash or assets, is its case against Cowan. Please don't pretend that there is any other current hope.